このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Esperion Therapeutics マネジメント

マネジメント基準チェック /34

Esperion Therapeutics'の CEO はSheldon Koenigで、 May2021年に任命され、の在任期間は 3.08年です。の年間総報酬は$ 2.97Mで、 24.3%給与と75.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.087%を直接所有しており、その価値は$ 471.21K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と2.9年です。

主要情報

Sheldon Koenig

最高経営責任者

US$3.0m

報酬総額

CEO給与比率	24.3%
CEO在任期間	3.1yrs
CEOの所有権	0.09%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

CEO報酬分析

Esperion Therapeutics の収益と比較して、Sheldon Koenig の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$87m
Dec 31 2023	US$3m	US$721k	-US$209m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$222m
Mar 31 2023	n/a	n/a	-US$239m
Dec 31 2022	US$4m	US$683k	-US$234m
Sep 30 2022	n/a	n/a	-US$243m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$8m	US$566k	-US$269m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$325m
Mar 31 2021	n/a	n/a	-US$156m
Dec 31 2020	US$508k	US$23k	-US$144m

報酬と市場: Sheldonの総報酬 ($USD 2.97M ) は、 US市場 ($USD 2.44M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Sheldonの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sheldon Koenig (58 yo)

3.1yrs

在職期間

US$2,968,565

報酬

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sheldon Koenig	President	3.1yrs	US$2.97m	0.087% $ 357.9k
JoAnne Foody	Chief Medical Officer	3yrs	US$1.42m	0.14% $ 596.8k
Eric Warren	Chief Commercial Officer	2.3yrs	US$1.08m	0.087% $ 361.0k
Benjamin Halladay	Chief Financial Officer	1.6yrs	データなし	0.13% $ 531.8k
Glenn Brame	Chief Technical Operations Officer	1.4yrs	データなし	データなし
Benjamin Looker	General Counsel & Corporate Secretary	2.4yrs	US$1.29m	0.097% $ 400.4k
Tiffany Aldrich	Associate Director of Corporate Communications	no data	データなし	データなし
Betty Swartz	Chief Business Officer	no data	データなし	データなし

2.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ESPRの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sheldon Koenig	President	3.1yrs	US$2.97m	0.087% $ 357.9k
Nicole Vitullo	Lead Independent Director	16.2yrs	US$94.78k	0.017% $ 69.3k
Alan Fuhrman	Independent Non-Employee Director	4.3yrs	US$104.78k	0.028% $ 116.4k
Antonio Gotto	Independent Director	10.4yrs	US$82.28k	0.027% $ 112.5k
Jay Shepard	Independent Director	6.1yrs	US$97.28k	0.027% $ 112.5k
Stephen Rocamboli	Independent Director	2.2yrs	US$94.78k	0.019% $ 79.1k
J. Carroll	Independent Chairperson	2yrs	US$117.28k	0.034% $ 140.9k
Peter Libby	Member of Scientific Advisory Board	1.8yrs	データなし	データなし
Seth H. Fischer	Independent Director	2.7yrs	US$99.78k	0.015% $ 61.4k
Tracy Woody	Independent Director	5.1yrs	US$91.97k	0.015% $ 62.0k
Erin Bohula	Member of Scientific Advisory Board	1.8yrs	データなし	データなし
Jeffrey Bender	Member of Scientific Advisory Board	1.8yrs	データなし	データなし

2.9yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: ESPRの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Esperion Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

High number of new directors

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Consensus EPS estimates upgraded to US$0.37 loss

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

Esperion Is Sitting On A Potential Blockbuster Drug

Forecast breakeven date pushed back to 2025

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Price target decreased by 18% to US$9.14

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Consensus EPS estimates upgraded to US$1.99 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Price target decreased by 10% to US$10.08

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 12% to US$12.22

Price target decreased by 11% to US$10.41

Consensus revenue estimates fall by 24%

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 20%

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$12.10

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Esperion Therapeutics Q2 2022 Earnings Preview

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

Esperion Therapeutics: 2021 Labors Paying Off In 2022

Price target increased to US$11.67

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

マネジメント基準チェック /34